Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study.
OBJECTIVE
The role of pharmacogenetics in chemotherapy response in colon carcinoma is controversial. We studied the value of known SNPs in genes involved in 5-FU metabolism as biomarkers of chemotherapy response in patients with stage III colon carcinoma.


METHODS
DNA was isolated from normal colonic tissue of 60 patients with stage III colon carcinoma treated adjuvantly with 5-FU combined with leucovorin. The tested SNPs were validated SNPs on the OPRT, TYMS and DPYD genes and a synonymous SNP on the TYMP gene. Real-time PCR, sequencing and RFLP were used for genotyping.


RESULTS
None of the studied genotypes was associated with any of the tumor or patient characteristics. Moreover, none of the genotypes studied had effect on patient survival.


CONCLUSIONS
In conclusion, the tested SNPs are not biomarkers of chemotherapy response in our stage III colon cancer patients group.
Fariña-Sarasqueta
Arantza
A
Department of Molecular Diagnostics, PAMM Laboratory of Pathology, Michelangelolaan 2, 5623 EJ Eindhoven, The Netherlands.
van Lijnschoten
Gesina
G
Rutten
Harm J T
HJ
van den Brule
Adriaan J C
AJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000235:genetics* / Q000556:secondary; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D005819:Genetic Markers; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010865:Pilot Projects; D012150:Polymorphism, Restriction Fragment Length; D020641:Polymorphism, Single Nucleotide; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D005819:Genetic Markers; D005472:Fluorouracil